Thirteen months. That is the median overall survival for patients with metastatic pancreatic cancer treated with Revolution Medicines’ new drug, daraxonrasib. In a field where progress is measured in weeks, this result is a seismic shift.

At the 2026 American Society of Clinical Oncology (ASCO) annual congress, the data from the Phase III RASolute 302 trial hit the plenary session with force. The drug, an oral RAS(ON) inhibitor, nearly doubled the survival time of the chemotherapy control arm. It didn't just meet its primary endpoints. It shattered them.

Why This Matters Now

Pancreatic cancer has long been a graveyard for targeted therapies. Most KRAS inhibitors, such as sotorasib, are limited by their inability to bind to the protein in its active state. They target the "off" switch. Daraxonrasib is different. It locks onto the protein while it is active, effectively silencing the tumor’s primary engine. Because of this mechanism, it can target up to 90 percent of KRAS-driven pancreatic tumors, including the notoriously difficult G12D and G12V mutations.

The Data Behind the Hype

The numbers from the RASolute 302 trial provide a clear picture of the drug's efficacy. Patients receiving daraxonrasib saw a median overall survival of 13.2 months, compared to just 6.7 months for those on chemotherapy. The hazard ratio of 0.40 indicates a massive reduction in the risk of death.

Progression-free survival also saw a significant jump, rising to 7.2 months from 3.6 months. Perhaps most striking is the objective response rate. At 31.6 percent, it is nearly triple the 11.2 percent seen in the chemotherapy group.

Safety remains a factor, but the profile is manageable. While 44 percent of patients experienced Grade 3 or higher adverse events, this was lower than the 58 percent seen in the chemotherapy arm. Discontinuation rates were remarkably low at 1.2 percent. Patients tolerated the drug well. That is a win.

The Path to Market

Revolution Medicines is not waiting. Armed with Breakthrough Therapy and Orphan Drug designations, the company is utilizing a National Priority Voucher to compress the FDA review timeline to roughly two months. Approval could come as early as this year.

But the company is already looking past second-line treatment. The Phase III RASolute 303 trial is currently enrolling first-line patients. Early data is aggressive, showing response rates of 47 percent as a monotherapy and 58 percent when combined with chemotherapy. If these numbers hold, the standard of care for pancreatic cancer is about to change forever.

Key Takeaways

  • Daraxonrasib doubled median overall survival to 13.2 months in the RASolute 302 trial, significantly outperforming chemotherapy.
  • The drug targets the active "on" state of the KRAS protein, allowing it to address 90 percent of KRAS-driven pancreatic tumors.
  • With a fast-tracked FDA review, the drug could reach the market within months, potentially shifting to first-line treatment if ongoing trials succeed.

What Experts Say

Oncologists at ASCO were notably optimistic. The ability to target the G12D and G12V mutations—long considered "undruggable"—represents a fundamental change in how the medical community approaches pancreatic ductal adenocarcinoma. While toxicity management remains a clinical necessity, the survival benefit provides a clear path forward for patients who previously had few options.

The Next Decision Point

Revolution Medicines’ next major milestone is the FDA’s final decision on the New Drug Application. With the priority voucher in play, the agency’s response is expected by late 2026. For the thousands of patients currently facing a metastatic diagnosis, the wait is no longer measured in years, but in weeks. The question is no longer if the drug works, but how quickly it can reach the clinic.